**WEDNESDAY December 6, 2017**

**Program Number: GS1-02**

**NSABP B-47 (NRG Oncology):** Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC).


**Presenter:** Louis Fehrenbacher  
**Session Title:** General Session 1 — Hall 3  
**Session Date & Time:** Wednesday 12-6-2017; 9:30 AM - 11:15 AM  
**Presentation Time:** 9:45 AM - 10:00 AM

---

**THURSDAY December 7, 2017**

**Program Number: P2-11-01**

**Effects of radiotherapy on breast cancer outcomes among stage I, low-recurrence risk, hormone-sensitive breast cancer: Pooled analysis of individual data from phase III trials.**


**Presenter:** Jayasekera, JC  
**Session Title:** Treatment: Radiotherapy  
**Location:** Poster Session 2 – Hall 1  
**Session Date & Time:** Thursday, 12-7-2017; 7:00 AM-9:00 AM

---

**Program Number: PD3-18**

**The NSABP/NRG 8-gene signature accurately predicts degree of benefit from trastuzumab in Alliance/NCCTG N9831: Validation of the 8-gene signature in an independent clinical trial.**

Pogue-Geile KL, Song N, Serie DJ, Thompson AE.

**Presenter:** Kay Pogue-Geile  
**Session Title:** Novel Drugs / Predicting Response for HER2+ Breast Cancer  
**Location:** Spotlight Poster Discussion 3 – Stars at Night Ballroom 1 & 2  
**Session Date & Time:** Thursday, 12-7-2017; 7:00 AM- 7:45 AM, Attend poster; 7:45 AM - 9 AM Poster discussion.
Abstracts to be Presented at 40th Annual SABCS — December 5-9, 2017

**THURSDAY December 7, 2017 con't**

Program Number: OT2-03-02
NRG Oncology/NSABP B-51/RTOG 1304: A phase III clinical trial to determine if chest wall and regional nodal radiotherapy post mastectomy or the addition of RNRT to breast RT post breast-conserving surgery reduces invasive cancer recurrence-free interval in patients with positive axillary nodes who are ypNO after neoadjuvant chemotherapy.
**Presenter:** Eleftherios P Mamounas

**Session Title:** Ongoing Trials - Radiotherapy

**Location:** Ongoing Trials Poster Session 2 – Hall 1

**Session Date & Time:** Thursday, 12-7-2017; 5:00 PM- 7:00 PM

**FRIDAY December 8, 2017**

Program Number: OT3-05-05
MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer.
Rastogi P, Toi M, Harbeck N, Bourayou N, Frenzel M, Johnston S.
**Presenter:** Priya Rastogi

**Session Title:** Ongoing Trials - Targeted- CDH 4/6

**Location:** Ongoing Trials Poster Session 3 – Hall 1

**Session Date & Time:** Friday, 12-8-2017; 5:00 PM- 7:00 PM